BACKGROUND: Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) in a cohort of breast cancer patients with bone-dominant metastases to determine response criteria. The thresholds for 95% specificity of change versus no-change were then applied to a second cohort of breast cancer patients with bone-dominant metastases. METHODS: For this study, nine patients with 38 bone lesions were imaged with 18F-FDG in the same calibrated scanner twice within 14 days. Tumor uptake was quantified by the most commonly used PET parameter, the maximum tumor voxel normalized by dose and body weight (SUVmax) and also by the mean of a 1-cc maximal uptake volume normalized by dose and lean-body-mass (SULpeak). The asymmetric repeatability coefficients with confidence intervals for SUVmax and SULpeak were used to determine the limits of 18F-FDG uptake variability. A second cohort of 28 breast cancer patients with bone-dominant metastases that had 146 metastatic bone lesions was imaged with 18F-FDG before and after standard-of-care therapy for response assessment. RESULTS: The mean relative difference of SUVmax and SULpeak in 38 bone tumors of the first cohort were 4.3% and 6.7%. The upper and lower asymmetric limits of the repeatability coefficient were 19.4% and - 16.3% for SUVmax, and 21.2% and - 17.5% for SULpeak. 18F-FDG repeatability coefficient confidence intervals resulted in the following patient stratification using SULpeak for the second patient cohort: 11-progressive disease, 5-stable disease, 7-partial response, and 1-complete response with three inevaluable patients. The asymmetric repeatability coefficients response criteria for SULpeak changed the status of 3 patients compared to the standard Positron Emission Tomography Response Criteria in Solid Tumors of ± 30% SULpeak. CONCLUSION: In evaluating bone tumor response for breast cancer patients with bone-dominant metastases using 18F-FDG SUVmax, the repeatability coefficients from test-retest studies show that reductions of more than 17% and increases of more than 20% are unlikely to be due to measurement variability. Serial 18F-FDG imaging in clinical trials investigating bone lesions in these patients, such as the ECOG-ACRIN EA1183 trial, benefit from confidence limits that allow interpretation of response.

Cleveland Clinic Cleveland OH USA

Department of Radiology University of Washington Medical Center 1959 NE Pacific Street UW Box 356465 Seattle Washington 98195 USA

Thomayer University Hospital Prague Czech Republic

University of Pennsylvania Philadelphia PA USA

Res Sq. 2024 Jan 16:rs.3.rs-3818932. doi: 10.21203/rs.3.rs-3818932/v1. PubMed

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69:7–34. doi: 10.3322/caac.21551. PubMed DOI

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:s6243–9. doi: 10.1158/1078-0432.ccr-06-0931. PubMed DOI

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6. doi: 10.1038/bjc.1987.13. PubMed DOI PMC

Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931–9. doi: 10.1043/1543-2165(2008)132[931:mpocrf]2.0.co;2. PubMed DOI

Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175–80. doi: 10.1002/jso.2930230311. PubMed DOI

Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, et al. [18F]-3’Deoxy-3’-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res. 2011;17:7664–72. doi: 10.1158/1078-0432.ccr-11-0783. PubMed DOI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–47. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

World Health O. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1428–37. doi: 10.1007/s00259-017-3703-7. PubMed DOI PMC

Cook GJR, Goh V. Molecular imaging of bone metastases and their response to Therapy. J Nucl Med. 2020;61:799–806. doi: 10.2967/jnumed.119.234260. PubMed DOI

Cook GJ, Azad GK, Goh V. Imaging bone metastases in breast Cancer: Staging and Response Assessment. J Nucl Med. 2016;57(Suppl 1):s27–33. doi: 10.2967/jnumed.115.157867. PubMed DOI

Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92. doi: 10.7150/jca.1.80. PubMed DOI PMC

Gallamini A, Zwarthoed C, Borra A. Positron Emission Tomography (PET) in Oncology. Cancers. 2014;6:1821–89. doi: 10.3390/cancers6041821. PubMed DOI PMC

Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(Suppl 1):S1–10. doi: 10.2967/jnumed.108.057174. PubMed DOI

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493–502. doi: 10.1016/s1470-2045(14)70475-9. PubMed DOI

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, et al. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56:31–7. doi: 10.2967/jnumed.114.144741. PubMed DOI PMC

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, et al. TBCRC026: phase II trial correlating standardized uptake value with pathologic complete response to Pertuzumab and Trastuzumab in breast Cancer. J Clin Oncol. 2019;37:714–22. doi: 10.1200/jco.2018.78.7986. PubMed DOI PMC

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res. 2011;17:2400–9. doi: 10.1158/1078-0432.ccr-10-2649. PubMed DOI PMC

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54:1862–8. doi: 10.2967/jnumed.112.119271. PubMed DOI

Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast Cancer. J Nucl Med. 2016;57(Suppl 1):s17–26. doi: 10.2967/jnumed.115.157859. PubMed DOI

Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, et al. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2018;45:1279–88. doi: 10.1007/s00259-018-3998-z. PubMed DOI

Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, et al. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Annals Oncology: Official J Eur Soc Med Oncol. 2012;23:2572–7. doi: 10.1093/annonc/mds071. PubMed DOI

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–47. doi: 10.1007/s00259-007-0379-4. PubMed DOI

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, et al. A phase II study of 3’-Deoxy-3’-18F-Fluorothymidine PET in the Assessment of early response of breast Cancer to Neoadjuvant Chemotherapy: results from ACRIN 6688. J Nucl Med. 2015;56:1681–9. doi: 10.2967/jnumed.115.160663. PubMed DOI PMC

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, et al. Phase II study of Lapatinib in Combination with Trastuzumab in patients with human epidermal growth factor receptor 2-Positive metastatic breast Cancer: clinical outcomes and predictive value of early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003) J Clin Oncol. 2015;33:2623–31. doi: 10.1200/jco.2014.60.0353. PubMed DOI PMC

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, et al. Updated results of TBCRC026: phase II trial correlating standardized uptake value with pathological complete response to Pertuzumab and Trastuzumab in breast Cancer. J Clin Oncol. 2021;39:2247–56. doi: 10.1200/jco.21.00280. PubMed DOI PMC

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82. doi: 10.1016/s0959-8049(99)00229-4. PubMed DOI

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122–50. doi: 10.2967/jnumed.108.057307. PubMed DOI PMC

Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55–66. doi: 10.1007/s00259-017-3687-3. PubMed DOI PMC

Pinker K. Advanced Imaging for Precision Medicine in breast Cancer: from morphology to function. Breast care (Basel Switzerland) 2017;12:208–10. doi: 10.1159/000480397. PubMed DOI PMC

Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189–96. doi: 10.1148/radiol.2471070567. PubMed DOI

Peterson LM, O’Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, et al. Prospective study of serial (18)F-FDG PET and (18)F-Fluoride PET to predict time to skeletal-related events, Time to Progression, and Survival in patients with Bone-Dominant metastatic breast Cancer. J Nucl Med. 2018;59:1823–30. doi: 10.2967/jnumed.118.211102. PubMed DOI PMC

Kinahan PE, Perlman ES, Sunderland JJ, Subramaniam R, Wollenweber SD, Turkington TG, et al. The QIBA Profile for FDG PET/CT as an imaging biomarker measuring response to Cancer Therapy. Radiology. 2020;294:647–57. doi: 10.1148/radiol.2019191882. PubMed DOI PMC

Macdonald LR, Schmitz RE, Alessio AM, Wollenweber SD, Stearns CW, Ganin A, et al. Measured count-rate performance of the Discovery STE PET/CT scanner in 2D, 3D and partial collimation acquisition modes. Phys Med Biol. 2008;53:3723–38. doi: 10.1088/0031-9155/53/14/002. PubMed DOI PMC

Byrd DW, Doot RK, Allberg KC, MacDonald LR, McDougald WA, Elston BF, et al. Evaluation of Cross-calibrated (68)Ge/(68)Ga Phantoms for assessing PET/CT Measurement Bias in Oncology Imaging for single- and Multicenter trials. Tomography. 2016;2:353–60. doi: 10.18383/j.tom.2016.00205. PubMed DOI PMC

Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, et al. Test-retest reproducibility of (18)F-FDG PET/CT uptake in Cancer patients within a qualified and calibrated local network. J Nucl Med. 2019;60:608–14. doi: 10.2967/jnumed.118.209544. PubMed DOI PMC

DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994;35:1398–406. PubMed

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, et al. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC) Mol Imaging Biology. 2014;16:431–40. doi: 10.1007/s11307-013-0699-7. PubMed DOI PMC

Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, et al. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med. 2009;50:1646–54. doi: 10.2967/jnumed.109.063347. PubMed DOI

Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, et al. Repeatability of 18F-FDG PET/CT in Advanced Non-small Cell Lung Cancer: prospective Assessment in 2 Multicenter trials. J Nucl Med. 2015;56:1137–43. doi: 10.2967/jnumed.114.147728. PubMed DOI PMC

Bland JM, Altman DG. Measurement error proportional to the mean. BMJ (clinical research ed). 1996;313:106. 10.1136/bmj.313.7049.106. PubMed PMC

Lipsitz SR, Laird NM, Harrington DP. Using the jackknife to estimate the variance of regression estimators from repeated measures studies. Commun Stat - Theory Methods. 1990;19:821–45. doi: 10.1080/03610929008830234. DOI

Muzi M, Peterson L, Novakova A, Lee J, Kurland B, Specht J, et al. Repeatability of 18F-FDG uptake values in bone lesions from breast cancer patients with metastatic bone disease. J Nucl Med. 2018;59:1369.

Tong S, Alessio AM, Kinahan PE. Evaluation of Noise Properties in PSF-Based PET Image Reconstruction. IEEE Nuclear Science Symposium conference record Nuclear Science Symposium. 2009;2009:3042-7. 10.1109/nssmic.2009.5401574. PubMed PMC

Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, et al. Reproducibility of 18F-FDG and 3’-deoxy-3’-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51:1368–76. doi: 10.2967/jnumed.110.078501. PubMed DOI

Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294–301. doi: 10.1007/s00259-004-1566-1. PubMed DOI

Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biology. 2002;4:171–8. doi: 10.1016/s1536-1632(01)00004-x. PubMed DOI